Lexicon Pharmaceuticals: Global INPEFA Expansion and Late-Stage Pipeline Catalysts Support Buy Rating and $4 Target

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals, with a price target of $4.00.

Joseph Pantginis has given his Buy rating due to a combination of factors that underscore both Lexicon’s expanding commercial footprint and its advancing late-stage pipeline. He points to the launch of INPEFA in the United Arab Emirates—its first heart failure market outside the U.S. and Europe—as an initial step in a broader global rollout that should open additional revenue channels as more countries approve the drug. The partnership with Viatris and ongoing regulatory filings in markets such as Canada, Australia, and Mexico support the view that international sales could become a meaningful growth driver over the next several years.

At the same time, Pantginis emphasizes that Lexicon’s value is increasingly tied to its late-stage R&D assets, particularly pilavapadin for diabetic peripheral neuropathic pain and sotagliflozin in hypertrophic cardiomyopathy. The SONATA Phase 3 trial in HCM, uniquely enrolling both obstructive and non‑obstructive patients across more than 130 global sites, offers a significant potential catalyst with topline data expected in 2027. He also highlights the planned resubmission of sotagliflozin (ZYNQUISTA) in type 1 diabetes, supported by additional safety data, as well as the progress of LX9851 in obesity under Novo Nordisk’s stewardship and associated milestone payments. Collectively, these commercial advances, late-stage clinical milestones, and partnered programs underpin his positive view on Lexicon’s risk‑reward profile and support his Buy recommendation and $4.00 price target.

In another report released on January 16, Piper Sandler also maintained a Buy rating on the stock with a $6.00 price target.